A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following Injury
Recruiting
Observational Study
Tetanus
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Sex
- Any
- Study type
- Observational
- Participants needed
- 10,000 (estimated)
- Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred. The registry will also employ selective safety data collection to record adverse reactions and serious adverse events following Siltartoxatug adminstration.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* 1.Having received or will receive Siltartoxatug for tetanus prophylaxis following injury;
* 2\. Provided signed informed consent by themselves or their legal representatives.
Exclusion Criteria:
* None
Contacts